Potential New Antidepressant Drug
Credit: Dr Sarah Bailey, Department of Pharmacy & Pharmacology, University of Bath
A potential new antidepressant and anti-anxiety treatment with a unique mechanism of action has been developed by scientists at the University of Bath.
The compound has shown significant potential after studies in mice. The research is published in the British Journal of Pharmacology.
Around one in six adults will experience depression in their lifetimes. New drugs to treat depression in particular are needed because many existing antidepressants don’t work in up to 50% of patients. This new University of Bath compound, known as BU10119, works in a different way to the most common antidepressant drugs; selective serotonin reuptake inhibitors (SSRIs), and may therefore offer a new potential treatment for those in whom SSRIs don’t work.
Unlike SSRIs which target the serotonin system in the brain, BU10119 works by blocking receptors called kappa opioid receptors. Blocking these receptors has been shown to have antidepressant like effects in mice.
In a series of laboratory trials, mice given BU10119 demonstrated behaviours consistent with providing antidepressant–like effects.
Dr Sarah Bailey, Senior Lecturer in the Department of Pharmacy & Pharmacology at the University of Bath, said: “I’m really quite excited by the potential of this compound. Developing new medicines is why I got into pharmacology and, in 20 years of research, this is the closest I have come to a new compound that might translate towards the clinic. It’s promising, but that said, we are still at an early stage, these experiments are in mice and further research is still required for example to establish safety.
“SSRIs can work very well for some patients, but we know they don’t work for everyone which is one reason why developing new antidepressant and anti-anxiety drugs could be really beneficial.”
Professor Stephen Husbands, Head of Medicinal Chemistry at the University of Bath added: “This research builds on our previous work which showed that combining buprenorphine and naltrexone can give antidepressant effects in mice. By combining the effects of both drugs in one molecule we hope that a safe and effective drug will eventually be the outcome. BU10119 is part of a series of compounds now licensed to, and under development with, Orexigen Therapeutics.”
This article has been republished from materials provided by University of Bath. Note: material may have been edited for length and content. For further information, please contact the cited source.
Almatroudi, A., Ostovar, M., Bailey, C. P., Husbands, S. M., & Bailey, S. J. (2017). Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice. British Journal of Pharmacology. doi:10.1111/bph.14060